Agreements reached under this partnership
Business alliance- 1
Neurocrine Biosciences, Inc. has acquired the research, development and commercialization rights to a broad portfolio of novel subtype-selective muscarinic M4, M1 and M1/M4 dual receptor agonists discovered by us and being developed for the treatment of major neurological disorders, at both clinical and preclinical stages.
- 2
Neurocrine Biosciences, Inc. will bear the global development costs related to this program, except for the M1 receptor agonist being developed in Japan.
- 3
We retain the development and commercialization rights in Japan for the muscarinic M1 receptor agonist for all indications, while Neurocrine Biosciences, Inc. holds an option to co-develop and co-commercialize the muscarinic M1 receptor agonist in Japan.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The full amount of this milestone is expected to be recognized as revenue in the third quarter of the fiscal year ending December 2026. The impact of this matter on our consolidated results for the fiscal year ending December 2026 has already been reflected in the consolidated earnings forecast for the fiscal year disclosed on 13 February 2026.
| Item | Details |
|---|---|
| Name of alliance partner | Neurocrine Biosciences Inc., Neurocrine Biosciences, Inc. |
| Alliance partner's business activities | Development of treatments for schizophrenia, dementia and other psychiatric and neurological disorders |
| Type of alliance | Business alliance |
| Details of the alliance | Neurocrine Biosciences, Inc. has acquired the research, development and commercialization rights to a broad portfolio of novel subtype-selective muscarinic M4, M1 and M1/M4 dual receptor agonists discovered by us and being developed for the treatment of major neurological disorders, at both clinical and preclinical stages., Neurocrine Biosciences, Inc. will bear the global development costs related to this program, except for the M1 receptor agonist being developed in Japan., We retain the development and commercialization rights in Japan for the muscarinic M1 receptor agonist for all indications, while Neurocrine Biosciences, Inc. holds an option to co-develop and co-commercialize the muscarinic M1 receptor agonist in Japan. |
| Contract Date | November 2021 |
| Impact on Business Performance | The full amount of this milestone is expected to be recognized as revenue in the third quarter of the fiscal year ending December 2026. The impact of this matter on our consolidated results for the fiscal year ending December 2026 has already been reflected in the consolidated earnings forecast for the fiscal year disclosed on 13 February 2026. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.A contractual milestone was triggered by the FDA's acceptance of the IND for NBI-1117567.